Life Sciences Tools and Services
Company Overview of Crown Bioscience, Inc.
Crown Bioscience, Inc., a preclinical CRO, provides drug discovery and development services to biotech and pharmaceutical partners focusing on oncology and metabolic disease therapeutic areas. The company’s proprietary HuPrime, HuKemia, HuBase, HuMark, HuTrial, and HuSignature platforms enable lead optimization and translational strategies to deliver clinical candidates. It offers oncology services, such as oncology databases, Ex vivo services, human surrogate trials, in vitro and in vivo services, preclinical formulations, translational research, and drug discovery services; and metabolic disease services, including in vivo and in vitro services, cardiovascular and metabolic disease (CVMD) ...
3375 Scott Boulevard
Santa Clara, CA 95054
Founded in 2006
Key Executives for Crown Bioscience, Inc.
Co-Founder and Chief Executive Officer
Senior Vice President of Operation and General Manager of Crownbio Taicang Facility
Compensation as of Fiscal Year 2015.
Crown Bioscience, Inc. Key Developments
Crown Bioscience, Inc. Expands Life Science Product Offering with Recombinant Cell Lines
Jun 23 15
Crown Bioscience, Inc. announced that is has added cell lines for biological studies and oncology drug screening to their Life Science division’s catalog. Three new categories of cell lines are available for purchase: EML4-ALK Kinase-Live cell lines are Crown’s stable Ba/F3 clones expressing exogenous EML4-ALK fusion variants, including wild type and L1196M, F1174L and C1156Y mutations. They are ideal for cell-based screening of potential ALK inhibitors that can overcome Crizotinib resistance. PD-1 and PD-L1 recombinant cell lines are HEK 293T cells stably expressing exogenous human PD-1 or PD-L1. They are recommended for PD-1 or PD-L1 inhibitor or antibody drug screening. Pathway Reporter cell lines that can be used to study the activation or inhibition of key intracellular signaling pathways involved in cancer and other diseases. The Wnt Pathway Reporter cell line is the first of these to be released. This cell line contains a stably integrated Wnt reporter expression cassette with the firefly luciferase gene. The Wnt reporter expression is robustly induced by exogenous Wnt stimulation, which can be easily measured by the luciferase activity. This cell line is intended for screening of inhibitors or activators of Wnt signaling pathway, which is frequently activated abnormally in many human cancers. The release of these cell lines, in combination with the company’s recently launched in vivo grade isotype controls, and diabetic and cancer tissue samples from relevant models, enhances Crown Bioscience’s mission to provide 'gold standard' services and tools to clients within preclinical drug discovery, and ultimately help reduce the attrition rate of candidate compounds in the clinic, before they enter the clinic.
Crown Bioscience, Inc. Presents at China Healthcare Investment Conference - Shanghai, Apr-01-2015 02:00 PM
Mar 28 15
Crown Bioscience, Inc. Presents at China Healthcare Investment Conference - Shanghai, Apr-01-2015 02:00 PM. Venue: Shangri-La Pudong Hotel, 33 Fu Cheng Road, Pudong, Shanghai 200120, China. Speakers: Guo-Liang Yu, Executive Chairman.
Crown Bioscience, Inc. Announces Partnership Agreement with National Resource Center for Mutant Mice
Feb 4 15
Crown Bioscience, Inc., has announced that a new partnership agreement has been reached with the National Resource Center for Mutant Mice (NRCMM) and its commercial branch Nanjing Biotech Innovation Corporation (NBIC), in Nanjing, Jiangsu Province, China. The newly expanded strategic partnership will focus on the development of new immune-oncology experimental cancer models, along with other models, including diabetes and inflammation diseases, to advance immune-oncology translational research and the treatment of cancers and other diseases. Immune-oncology therapy has recently become an area of intense cancer pharmaceutical research, particularly with the recent regulatory approval of PD-1 antibody for the treatment of cancer.
Similar Private Companies By Industry
Recent Private Companies Transactions